Erman Akkus Summarizes 5-year Results of CheckMate 040

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:

“Nivolumab plus ipilimumab after sorafenib in patients with advanced HCC
5-year results of CheckMate 040
Annals of Oncology

Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg Q3W (four doses), followed by nivolumab 240 mg Q2W

• ORR: 34%
• mDOR: 51.2 mo
• mOS: 22.2 mo
• 60-month OS rate: 29%″

Read the article.
Source: Erman Akkus/X
.